We screened four patient-derived tumor organoid (PDTO) lines against two compounds and read out the same wells twice: once by brightfield imaging analysed with Orbits 2.0, and once with CellTiter-Glo 3D (CTG). Orbits 2.0 reproduced CTG potency and delivered markedly tighter replicates and robust assay quality — without dyes and without lysis. Because Orbits 2.0 segments viable and dead organoids label-free, its growth-rate metric (NOGR) also distinguishes cytostatic from cytotoxic drug effects: information an ATP endpoint cannot provide.
Luminescent ATP assays such as CellTiter-Glo 3D are the default viability readout in organoid screening. They are simple, but they are destructive, give one timepoint per well, and depend on complete lysis and ATP extraction from 3D structures — a step that is difficult to control in dense, large or heterogeneous organoid cultures.
Imaging-based analysis keeps every well alive and measurable over time. The first generation of Orbits (1.0) already quantified organoids label-free in brightfield, but still relied on a fluorescent dead-cell dye to separate viable from dead organoid area.
Orbits 2.0 removes that dependency. A new segmentation and cell-death classification model identifies viable and dead organoid area directly from brightfield images (Figure 1), so a screen needs nothing more than the organoids, the compounds and an imager.
Normalised to the untreated and positive-control wells of each line, Orbits 2.0 viable organoid area and CTG luminescence produced overlapping dose-response curves (Figure 2). For Compound 1, where all readouts gave an EC50 within the tested range, Orbits 2.0 potencies were within 1.05–1.32-fold of CTG (r = 0.98, median ratio 1.12×, Figure 3d; e.g. CRC001 181 vs 190 nM, LU001N 91 vs 98 nM). Compound 2 was more potent than the lowest tested dose in all lines by imaging. By CTG, scattered low-dose wells reading up to twice the untreated signal distorted two of the four fits.
Every screen stands or falls with its controls, so we start there. Figure 3a shows each untreated well relative to the median of its line: if a readout is reliable, all points sit close to 1×. The Orbits 2.0 wells do (CV 13–18%), and even more tightly after each well is normalised to its own T0 image (CV 7–10%). The CTG wells do not: CVs of 31–76%, and 11 of the 64 untreated wells read two to four times their line median (shaded area). No Orbits 2.0 control well came close.
These control wells set the assay quality, summarised by the Z′-factor (Figure 3b): it compares the gap between untreated and positive-control wells with their spread. Above 0.4 is good and above 0.7 excellent; below 0 the two control groups overlap and hits cannot be called reliably. Because of its erratic controls, CTG fell below 0 in 3 of 4 lines (median -0.57). Orbits 2.0 reached a median of 0.47 from the endpoint image alone and 0.73 with T0 normalisation, excellent in 3 of 4 lines. That second step is only possible because imaging leaves every well intact.
The same difference appears in the treated wells (Figure 3c). At doses where organoids were still alive — the part of the curve that defines potency — replicate CTG wells typically differed by 68% of the assay window, against 10% for Orbits 2.0. At doses that killed the organoids, both readouts were equally tight (1%). The extra CTG noise therefore sits exactly where the biology is, which explains the scattered CTG wells in Figure 2. Despite this, both readouts rank compound potency the same way (Figure 3d).
A CTG signal below the untreated control shows that a drug worked, but not how: organoids may have grown less, or died. Orbits separates the two because it segments viable and dead organoids label-free in every image, measuring viable organoid area directly rather than a proxy such as ATP.
The Normalised Organoid Growth Rate (NOGR) expresses the change in each well's viable area from T0 to the endpoint, scaled to the untreated and positive-control wells. Comparing each well with its own starting point removes differences in seeding, which improves reproducibility. The same metric also shows how a drug acts: values from 1 to 0 are cytostatic (organoids still grow, but less than untreated; 0 means complete growth arrest), and values from 0 to −1 are cytotoxic (viable organoid area is lost; −1 matches the positive control).
Orbits 1.0 already reported NOGR, but needed Cytotox Green and a second imaging channel to identify dead organoid area. Orbits 2.0 does this from brightfield alone (Figure 1). We compared both versions on the same wells.
The NOGR curves of Orbits 1.0 and 2.0 overlap in every line and resolve both the cytostatic and the cytotoxic range (Figure 4a). Replicate wells were tighter with Orbits 2.0 in 7 of 8 dose-response curves (Figure 4b), and the T0-normalised assay quality rose from a median Z′ of 0.56 to 0.73, with every line in the good-to-excellent range (Figure 4c). Potency was unchanged: the concentration that halves organoid growth (NOGR50) agreed between versions with r = 0.99 (Figure 4d). Dropping the dye therefore costs nothing — it improves the readout.
| CellTiter-Glo 3D | Orbits 1.0 | Orbits 2.0 | |
|---|---|---|---|
| Reagents added to the well | ATP detection reagent (lytic) | Cytotox Green dye | None |
| Wells remain intact | ✕ endpoint only | ✓ | ✓ |
| Timepoints per well | 1 | Multiple (kinetic) | Multiple (kinetic) |
| Cytostatic vs cytotoxic (NOGR) | ✕ | ✓ | ✓ |
| Replicate SD at viable doses (median) | 68% | 14% | 10% |
| Median Z′ (endpoint / T0-norm.) | -0.57 / not possible | 0.46 / 0.56 | 0.47 / 0.73 |
| Imaging channels required | — | Brightfield + green fluorescence | Brightfield |
| Per-organoid size, count, morphology | ✕ | ✓ | ✓ |
PDTOs were seeded in 384-well plates and imaged in brightfield and green fluorescence at T0 and at the endpoint after 120 h on a Tecan Spark Cyto, following the protocol described in ref. 3; CellTiter-Glo 3D was added to the same wells after the final image. Viable organoid area per well was quantified with Orbits 1.0 (brightfield organoid area minus Cytotox Green-positive area) and Orbits 2.0 (brightfield-only segmentation and label-free death classification; the green channel was not used). Endpoint readouts were normalised per line to the median untreated (100%) and positive-control (0%; Compound 2 at 5000 nM) wells. NOGR was calculated from the T0-to-endpoint change in viable area and scaled to the untreated (1) and positive-control (−1) medians (ref. 2). Dose-responses were fitted with a three-parameter log-logistic model with the top fixed at 100% (or NOGR = 1). Replicate variability is the SD of the five wells per dose. Z′ = 1 − 3(SDpos + SDneg)/|meanpos − meanneg|. No wells were excluded. Data are from a single experiment with four PDTO lines and two compounds; CTG performance depends on assay optimisation and may differ in other settings.
1. Deben C, et al. OrBITS: label-free and time-lapse monitoring of patient-derived organoids for advanced drug screening. Cellular Oncology (2022). doi:10.1007/s13402-022-00750-0
2. Deben C, et al. Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. Communications Biology 7:1612 (2024). doi:10.1038/s42003-024-07329-5
3. Le Compte M, et al. Multiparametric tumor organoid drug screening using widefield live-cell imaging for bulk and single-organoid analysis. Journal of Visualized Experiments (190):e64434 (2022). doi:10.3791/64434
Orbits started in 2019 at the University of Antwerp, where cancer biologists and biomedical engineers set out to make 3D in vitro models reproducible and scalable. The Orbits platform turns live-cell imaging of organoids, spheroids and other complex in vitro models into quantitative readouts: segmentation, cell-death classification, growth rate and drug-response metrics, across imaging systems and plate formats. Orbits Oncology was incorporated in the United States in 2023.
Send us a plate you have already run with CellTiter-Glo and brightfield images, and we will analyse it side by side with Orbits 2.0 — so you can judge the difference on your own models, compounds and imager.
Book a demoDownload PDFinfo@orbits-oncology.comorbits-oncology.com